Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Administration of HspB5 was therapeutic in animal models of multiple sclerosis, retinal and cardiac ischemia, and stroke.
|
30249602 |
2019 |
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
αB-crystallin is a heat-shock protein induced in cells undergoing cellular stress and has been reported to be up-regulated in both multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
|
30578556 |
2019 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting extracellular CRYAB-modulated neuroinflammation is a potential therapeutic intervention for MS.
|
30497777 |
2019 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we reveal that CRYAB is differentially phosphorylated in astrocytes in active demyelinating MS lesions, as well as in cuprizone-induced lesions, and that this phosphorylation is required for the reactive astrocyte response associated with demyelination.
|
28196893 |
2017 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our data suggest that preactive MS lesions are at least in part driven by HspB5 derived from stressed oligodendrocytes and may reflect a local attempt to restore tissue homeostasis.
|
24042199 |
2013 |
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD4(+) T cells from healthy controls and volunteers with MS were activated in vitro in the presence or absence of a CRYAB peptide (residues 73-92).
|
23736536 |
2013 |
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) in the promoter region of CRYAB gene have been associated with in multiple sclerosis.
|
22537749 |
2012 |
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CRYAB promoter polymorphisms: influence on multiple sclerosis susceptibility and clinical presentation.
|
17010329 |
2007 |
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination.
|
17568699 |
2007 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
This comparison revealed that among ocular antigens, alpha B-crystallin is the dominant target antigen for serum autoantibodies in both MS patients and healthy controls.
|
16764341 |
2006 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings suggest that autoreactive alpha B-crystallin-specific Th1 cells may have the potential to contribute to MS pathogenesis.
|
14743435 |
2004 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
Taken together, these findings suggest that autoreactive alpha B-crystallin-specific Th1 cells may have the potential to contribute to MS pathogenesis.
|
14743435 |
2004 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the peripheral response towards the myelin antigen alpha B-crystallin is neither quantitatively nor qualitatively peculiar to MS, in contrast to the theoretical paradigm suggesting peripheral activation of myelin-reactive T cells to be the prerequisite for MS induction.
|
12940843 |
2003 |
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
[Alpha]B-crystallin is a candidate autoantigen in MS, and there are three polymorphisms in the promoter region of the encoding gene (CRYAB): at positions -C249G, -C650G, and -A652G.
|
14610128 |
2003 |
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We recently identified the small heat-shock protein alpha B-crystallin as the single immunodominant myelin antigen in MS-affected myelin.
|
8862510 |
1996 |